Keytruda nabs another priority review; Quell ties up CAR pact with Hannover Medical School
→ Add another priority review for Merck’s Keytruda. Unlike most FDA submissions, this one comes not for a particular cancer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
